Klimaktoplan tabletes Летонија - Летонски - Zāļu valsts aģentūra

klimaktoplan tabletes

alpen pharma gmbh, germany - cimicifuga, sepia officinalis, ignatia rūgta, katru dienu - tablete

Arlevert 20 mg/40 mg tabletes Летонија - Летонски - Zāļu valsts aģentūra

arlevert 20 mg/40 mg tabletes

hennig arzneimittel gmbh & co.kg, germany - cinnarizinum, dimenhydrinatum - tablete - 20 mg/40 mg

Oyavas Европска Унија - Летонски - EMA (European Medicines Agency)

oyavas

stada arzneimittel ag - bevacizumab - colorectal neoplasms; breast neoplasms; ovarian neoplasms; fallopian tube neoplasms; peritoneal neoplasms; carcinoma, non-small-cell lung; carcinoma, renal cell; uterine cervical neoplasms - antineoplastiski līdzekļi - oyavas in combination with fluoropyrimidine based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. oyavas in combination with paclitaxel is indicated for first line treatment of adult patients with metastatic breast cancer. papildinformāciju par cilvēka epidermas augšanas faktora 2 receptora (her2) statusu, lūdzu, skatiet 5. sadaļā. oyavas in combination with capecitabine is indicated for first line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. patients who have received taxane and anthracycline containing regimens in the adjuvant setting within the last 12 months should be excluded from treatment with oyavas in combination with capecitabine. sīkāku informāciju par her2 statusu, lūdzu, skatiet 5. sadaļā. oyavas, in addition to platinum based chemotherapy, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent non small cell lung cancer other than predominantly squamous cell histology. oyavas, in combination with erlotinib, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent non squamous non small cell lung cancer with epidermal growth factor receptor (egfr) activating mutations (see section 5. oyavas in combination with interferon alfa 2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer. oyavas, in combination with carboplatin and paclitaxel is indicated for the front line treatment of adult patients with advanced (international federation of gynecology and obstetrics (figo) stages iii b, iii c and iv) epithelial ovarian, fallopian tube, or primary peritoneal cancer (see section 5. oyavas, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor–targeted agents. oyavas, in combination with topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor targeted agents (see section 5. oyavas, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix (see section 5.

Axhidrox 2,2 mg/dozējumā krēms Летонија - Летонски - Zāļu valsts aģentūra

axhidrox 2,2 mg/dozējumā krēms

dr. august wolff gmbh & co. kg arzneimittel, germany - glikopironijs - krēms - 2,2 mg/dozējumā

Xenical Европска Унија - Летонски - EMA (European Medicines Agency)

xenical

cheplapharm arzneimittel gmbh - orlistat - aptaukošanās - pretiekaisuma līdzekļi, izņemot diētas produkti - xenical, ir minēta kopā ar maigi hypocaloric uzturs aptaukošanās pacientiem ar ķermeņa masas indeksa (bmi) lielāks vai vienāds ar 30 kg/m2 jeb liekais svars pacientiem (Ķmi > 28 kg/m2) ar saistītos riska faktorus apstrādes. Ārstēšana ar orlistat būtu jāpārtrauc pēc 12 nedēļas, ja pacients nav bijis iespējams zaudēt vismaz 5% no ķermeņa svara, kas mēra sākumā terapija.

Canifug Cremolum 200 mg pesāriji Летонија - Летонски - Zāļu valsts aģentūra

canifug cremolum 200 mg pesāriji

dr. august wolff gmbh & co. kg arzneimittel, germany - klotrimazols - pesārijs - 200 mg

Tavegyl 1 mg tabletes Летонија - Летонски - Zāļu valsts aģentūra

tavegyl 1 mg tabletes

stada arzneimittel ag, germany - klemastīns - tablete - 1 mg

Canifug Cremolum, 10 mg/g + 100 mg, krēms + pesāriji Летонија - Летонски - Zāļu valsts aģentūra

canifug cremolum, 10 mg/g + 100 mg, krēms + pesāriji

dr. august wolff gmbh & co. kg arzneimittel, germany - klotrimazols - krēms + pesārijs - 10 mg/g + 100 mg

Metrosa 7,5 mg/g gels Летонија - Летонски - Zāļu valsts aģentūra

metrosa 7,5 mg/g gels

dr. august wolff gmbh & co. kg arzneimittel, germany - metronidazols - gels - 7,5 mg/g

Arilin 250 mg apvalkotās tabletes un 100 mg pesāriji, kombinēts iepakojums Летонија - Летонски - Zāļu valsts aģentūra

arilin 250 mg apvalkotās tabletes un 100 mg pesāriji, kombinēts iepakojums

dr. august wolff gmbh & co. kg arzneimittel, germany - metronidazols - apvalkotā tablete + pesārijs - 250 mg/100 mg